Literature DB >> 20643596

CHEK2 gene alterations in the forkhead-associated domain, 1100delC and del5395 do not modify the risk of sporadic pancreatic cancer.

Beatrice Mohelnikova-Duchonova1, Ondrej Havranek, Ivona Hlavata, Lenka Foretova, Zdenek Kleibl, Petr Pohlreich, Pavel Soucek.   

Abstract

Checkpoint kinase 2 gene (CHEK2) alterations increase risk of several cancer types. We analyzed selected CHEK2 alterations in 270 Czech pancreatic cancer patients and in 683 healthy controls. The pancreatic cancer risk was higher in individuals who inherited rare alterations in CHEK2 region involving forkhead-associated domain other than I157T (OR=5.14; 95% CI=0.94-28.23) but the observed association was non-significant (p=0.057). The most frequent I157T mutation did not alter the pancreatic cancer risk and neither the followed deletion of 5395bp nor c.1100delC were found in any of pancreatic cases. We conclude that the I157T, other alterations in its proximity, del5395 and c.1100delC in CHEK2 do not predispose to pancreatic cancer risk in the Czech population.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20643596     DOI: 10.1016/j.canep.2010.06.008

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  8 in total

1.  Germline Variants and Risk for Pancreatic Cancer: A Systematic Review and Emerging Concepts.

Authors:  Wei Zhan; Celeste A Shelton; Phil J Greer; Randall E Brand; David C Whitcomb
Journal:  Pancreas       Date:  2018-09       Impact factor: 3.327

Review 2.  CHEK2 (∗) 1100delC Mutation and Risk of Prostate Cancer.

Authors:  Victoria Hale; Maren Weischer; Jong Y Park
Journal:  Prostate Cancer       Date:  2014-11-06

3.  An association study between CHEK2 gene mutations and susceptibility to breast cancer.

Authors:  Manizheh Jalilvand; Mana Oloomi; Reza Najafipour; Safar Ali Alizadeh; Najmaldin Saki; Fatemeh Samiee Rad; Mohammad Shekari
Journal:  Comp Clin Path       Date:  2017-04-08

Review 4.  CHEK2 Germline Variants in Cancer Predisposition: Stalemate Rather than Checkmate.

Authors:  Lenka Stolarova; Petra Kleiblova; Marketa Janatova; Jana Soukupova; Petra Zemankova; Libor Macurek; Zdenek Kleibl
Journal:  Cells       Date:  2020-12-12       Impact factor: 6.600

Review 5.  PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA.

Authors:  Emily N Risdon; Cindy H Chau; Douglas K Price; Oliver Sartor; William D Figg
Journal:  Oncologist       Date:  2020-09-08       Impact factor: 5.837

6.  Study on the Mechanism of Cell Cycle Checkpoint Kinase 2 (CHEK2) Gene Dysfunction in Chemotherapeutic Drug Resistance of Triple Negative Breast Cancer Cells.

Authors:  Li Luo; Wei Gao; Jinghui Wang; Dingxue Wang; Xiaobo Peng; Zhaoyang Jia; Ye Jiang; Gongzhuo Li; Dongxin Tang; Yajie Wang
Journal:  Med Sci Monit       Date:  2018-05-15

7.  Genetic analysis of subsequent second primary malignant neoplasms in long-term pancreatic cancer survivors suggests new potential hereditary genetic alterations.

Authors:  Martin Lovecek; Marketa Janatova; Pavel Skalicky; Tomas Zemanek; Roman Havlik; Jiri Ehrmann; Ondrej Strouhal; Petra Zemankova; Klara Lhotova; Marianna Borecka; Jana Soukupova; Hana Svebisova; Pavel Soucek; Viktor Hlavac; Zdenek Kleibl; Cestmir Neoral; Bohuslav Melichar; Beatrice Mohelnikova-Duchonova
Journal:  Cancer Manag Res       Date:  2019-01-10       Impact factor: 3.989

8.  A whole-exome case-control association study to characterize the contribution of rare coding variation to pancreatic cancer risk.

Authors:  Yao Yu; Kyle Chang; Jiun-Sheng Chen; Ryan J Bohlender; Jerry Fowler; Di Zhang; Maosheng Huang; Ping Chang; Yanan Li; Justin Wong; Huamin Wang; Jian Gu; Xifeng Wu; Joellen Schildkraut; Lisa Cannon-Albright; Yuanqing Ye; Hua Zhao; Michelle A T Hildebrandt; Jennifer B Permuth; Donghui Li; Paul Scheet; Chad D Huff
Journal:  HGG Adv       Date:  2021-12-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.